Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465

Experimental Dermatology

Volumn 19, Issue 12, 2010, Pages 1040-1047

  Pirker, Christine ^a   Lötsch, Daniela ^a,b   Spiegl Kreinecker, Sabine ^b   Jantscher, Florian ^a   Sutterlüty, Hewig ^a   Micksche, Michael ^a   Grusch, Michael ^a   Berger, Walter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

20q amplification; Aurora kinase A; Aurora kinase B; Human malignant melanoma; Therapy target; VE 465

Indexed keywords

AURORA KINASE INHIBITOR; DNA; GENOMIC DNA; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VE 465;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; EXPERIMENTAL MODEL; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MELANOMA; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN CANCER; TREATMENT RESPONSE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CASPASE 7; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMES, HUMAN; DRUG SYNERGISM; GENE AMPLIFICATION; HCT116 CELLS; HUMANS; MELANOMA; NEOPLASTIC STEM CELLS; PIPERAZINES; POLYPLOIDY; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649497606     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2010.01182.x     Document Type: Article

References (46)

1. Gray-Schopfer V, Wellbrock C, Marais R. Nature 2007: 445: 851-857.
2. La Porta C A. Curr Cancer Drug Targets 2009: 9: 391-397.
3. Dhomen N, Marais R. Hematol Oncol Clin North Am 2009: 23: 529-545.
4. Satyamoorthy K, Herlyn M. Cancer Biol Ther 2002: 1: 14-17.
5. Vader G, Lens S M. Biochim Biophys Acta 2008: 1786: 60-72.
6. Gautschi O, Heighway J, Mack P C et al. Clin Cancer Res 2008: 14: 1639-1648.
7. Zhou H, Kuang J, Zhong L et al. Nat Genet 1998: 20: 189-193.
8. Macurek L, Lindqvist A, Lim D et al. Nature 2008: 455: 119-123.
9. Seki A, Coppinger J A, Jang C Y et al. Science 2008: 320: 1655-1658.
10. Yang H, Ou C C, Feldman R I et al. Cancer Res 2004: 64: 463-467.
11. Ewart-Toland A, Briassouli P, De Koning J P et al. Nat Genet 2003: 34: 403-412.
12. Ota T, Suto S, Katayama H et al. Cancer Res 2002: 62: 5168-5177.
13. Kanda A, Kawai H, Suto S et al. Oncogene 2005: 24: 7266-7272.
14. Slattery S D, Mancini M A, Brinkley B R et al. Cell Cycle 2009: 8: 2984-2994.
15. Dreier M R, Grabovich A Z, Katusin J D et al. Exp Cell Res 2009: 315: 1085-1099.
16. Berger W, Hauptmann E, Elbling L et al. Int J Cancer 1997: 71: 108-115.
17. Dornetshuber R, Heffeter P, Kamyar M R et al. Chem Res Toxicol 2007: 20: 465-473.
18. Van Der Meijden C M, Lapointe D S, Luong M X et al. Cancer Res 2002: 62: 3233-3243.
19. Spiegl-Kreinecker S, Pirker C, Marosi C et al. Br J Cancer 2007: 96: 960-969.
20. Fischer H, Taylor N, Allerstorfer S et al. Mol Cancer Ther 2008: 7: 3408-3419.
21. Grusch M, Polgar D, Gfatter S et al. Cell Death Differ 2002: 9: 169-178.
22. Pirker C, Holzmann K, Spiegl-Kreinecker S et al. Melanoma Res 2003: 13: 483-492.
23. Honda K, Mihara H, Kato Y et al. Oncogene 2000: 19: 2812-2819.
24. Kaestner P, Stolz A, Bastians H. Mol Cancer Ther 2009: 8: 2046-2056.
25. Kojima K, Konopleva M, Tsao T et al. Blood 2008: 112: 2886-2895.
26. Box N F, Terzian T. Pigment Cell Melanoma Res 2008: 21: 525-533.
27. Rollig C, Illmer T. Cancer Treat Rev 2009: 35: 425-430.
28. Gadea B B, Ruderman J V. Mol Biol Cell 2005: 16: 1305-1318.
29. Barks J H, Thompson F H, Taetle R et al. Genes Chromosomes Cancer 1997: 19: 278-285.
30. Katayama H, Brinkley W R, Sen S. Cancer Metastasis Rev 2003: 22: 451-464.
31. Vucic D, Stennicke H R, Pisabarro M T et al. Curr Biol 2000: 10: 1359-1366.
32. Quinlan K G, Verger A, Yaswen P et al. Biochim Biophys Acta 2007: 1775: 333-340.
33. Koynova D K, Jordanova E S, Milev A D et al. Melanoma Res 2007: 17: 37-41.
34. Furukawa T, Kanai N, Shiwaku H O et al. Oncogene 2006: 25: 4831-4839.
35. Smalley K S. J Invest Dermatol 2010: 130: 28-37.
36. Spinella F, Rosano L, Di Castro V et al. Cancer Res 2007: 67: 1725-1734.
37. Gizatullin F, Yao Y, Kung V et al. Cancer Res 2006: 66: 7668-7677.
38. Andreassen P R, Lohez O D, Lacroix F B et al. Mol Biol Cell 2001: 12: 1315-1328.
39. Giet R, Glover D M. J Cell Biol 2001: 152: 669-682.
40. Donato N J, Fang D, Sun H et al. Biochem Pharmacol 2010: 79: 688-697.
41. McGill G G, Horstmann M, Widlund H R et al. Cell 2002: 109: 707-718.
42. VanderPorten E C, Taverna P, Hogan J N et al. Mol Cancer Ther 2009: 8: 930-939.
43. Hata T, Furukawa T, Sunamura M et al. Cancer Res 2005: 65: 2899-2905.
44. Li J, Anderson M G, Tucker L A et al. Cell Death Differ 2009: 16: 498-511.
45. Becker J C, Houben R, Schrama D et al. Exp Dermatol 2010: 19: 157-164.
46. Emanuel S, Rugg C A, Gruninger R H et al. Cancer Res 2005: 65: 9038-9046.